Clinical Trial: A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Study Status: Completed
Recruit Status: RECRUITING
Condition: Myelodysplastic Syndromes
Study Type: INTERVENTIONAL
Official Title: A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Read more